Therma Bright Inc. (TSXV:THRM), a Canadian medical tech stock, jumped after announcing that its partner has identified polypeptides for COVID-19 detection
A possible breakthrough in COVID-19 detection powered a Canadian medical tech stock Thursday. Here’s some small stocks making big moves on Thursday, September 3, 2020 (as of 4 pm EST):
Therma Bright Inc. (TSXV:THRM), a Canadian medical tech stock, climbed 11% to $0.155 on Thursday after announcing that its co-development partner, Orpheus Medica Inc., has identified a series of polypeptides for the screening and detection of the virus causing COVID-19.
As well, shares of Nexus Gold Corp. (TSXV:NXS) sank 14% to $0.095 as the gold explorer said it has received additional assay results from the recently-completed Phase One drill program at its 100% owned McKenzie Gold Project located in Red Lake, Ontario, which included 117.5 meters of 0.62 grams per tonne (g/t) gold.
Orosur Mining Inc. (TSX:OMI), meanwhile, reported that Newmont Corporation intends to continue to exercise its rights and obligations with regard to the Anzá gold project in Colombia, which includes making a final cash payment of US$500,000. Orosur Mining stock moved up 44% to $0.13 following the announcement.
Finally, General Moly, Inc. (TSX:GMO) shares gained as much as 13% after the molybdenum development company announced that it has entered into a binding letter of intent to sell its Liberty Project to Pathfinder Minerals LLC for a total consideration of up to $3 million.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Therma Bright Inc. (TSXV:THRM), a Canadian medical tech stock, climbed 11% to $0.155 on Thursday after announcing that its co-development partner, Orpheus Medica Inc., has identified a series of polypeptides for the screening and detection of the virus causing COVID-19.
, on Thursday.){kind=link}